TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21683485
Drug: Specially formulated
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specially formulated medical food (40 g protein, enriched with 10% free leucine)
Study: 21683485
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical food (24 g casein protein)
Study: 19921981
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice 50 ml daily (n=28)
Study: 19921981
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG drink 100 ml on 5 days a month (n=27)
Study: 15855510
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg intravenous infusion over 30 min t.i.d.
Study: 15855510
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg loading dose followed by 1,500 mg continuous infusion over 24 h
Study: 15855510
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg intravenous infusion over 30 min t.i.d.
Study: 15855510
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg loading dose followed by 3,000 mg continuous infusion over 24 h
Study: 15855510
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion
Study: 15855510
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy as continuous infusion
Study: 12791417
Drug: NN2211 (GLP-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN2211 (GLP-1 derivative), dose levels: eight, administered before glucose dose
Study: 7875920
Drug: Waking analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waking analgesia followed by hypnotic analgesia
Study: 7875920
Drug: Hypnotic analgesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic analgesia followed by waking analgesia
Study: 30687908
Drug: Non-ablative vaginal
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ablative vaginal erbium:YAG laser (VEL) treatment (20 min/session, thrice)
Study: 30687908
Drug: Anticholinergic agent
Normalized name: ANTICHOLINERGIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic agent (4 mg fesoterodine)
Study: 30687908
Drug: β3-adrenoceptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: β3-adrenoceptor agonist (25 mg mirabegron)
Study: 29055680
Drug: 24 IU
Normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24 IU intranasal OXT
Study: 26567120
Drug: Antihypotensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypotensive therapy
Study: 26567120
Drug: No antihypotensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antihypotensive therapy
Study: 19149837
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone replacement therapy (HRT) - continuous 17-beta estradiol patch at 36 microg/day plus cyclic oral medroxyprogesterone acetate 2.5 mg/day for 12 days/month
Study: 17017752
Drug: Ayurvedic intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ayurvedic intervention (exercise, Ayurvedic diet, meditation instruction, Ayurvedic herb supplement MA 471)
Study: 12834197
Drug: CC atrophy
Normalized name: Jatropha curcas seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC atrophy in CDR 1 & 2 patients
Study: 12834197
Drug: Frontal executive
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frontal executive dysfunction associated with CC atrophy
Study: 12834197
Drug: CC atrophy
Normalized name: Jatropha curcas seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC atrophy and WMH correlation
Study: 12834197
Drug: Combined effect
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined effect of CC atrophy and WMH in verbal fluency test
Study: 9315426
Drug: Various HIV-related
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various HIV-related medications
Study: 1535110
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for myocardial infarction (exact treatments not specified)
Study: 1535110
Drug: Treatments with
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments with no effect on mortality or potentially harmful treatments (control group)
Study: 4077377
Drug: Collagen protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen protein (1.3 g/kg desirable body weight per day)
Study: 4077377
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (1.3 g/kg desirable body weight per day)
Study: 29931143
Drug: Oxandrolone (Ox)
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone (Ox) 0.05 mg/kg for 2 years
Study: 23279918
Drug: Brief Motivational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Motivational Interviewing (BMI) in conjunction with Traditional Oral Health Education (TOHE) (n = 29)
Study: 23279918
Drug: Traditional Oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Oral Health Education (TOHE) alone (n = 27)
Study: 16749288
Drug: Coronary reperfusion
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary reperfusion therapy
Study: 11714046
Drug: Piperacillin/Tazobactam (100/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/Tazobactam (100/12.5 mg/kg every 8 h)
Study: 11714046
Drug: Cefotaxime plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime plus Metronidazole (50/7.5 mg/kg every 8 h)
Study: 7533224
Drug: Moxonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (0.2 mg b.i.d.)
Study: 3216030
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral tablet of dilevalol
Study: 3216030
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intravenous infusion of dilevalol
Study: 29193419
Drug: Artichoke leaf
Normalized name: artichoke leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artichoke leaf extract (ALE) supplementation (1,800 mg hydroalcoholic extract as four tablets per day)
Study: 29193419
Drug: Placebo (corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (corn starch, lactose, and avicel as four tablets per day)
Study: 24193155
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg every 8 weeks (q8w)
Study: 21241207
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg every 12 weeks (q12w)
Study: 21241207
Drug: Infliximab 10
Normalized name: infliximab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab 10 mg/kg every 8 weeks (q8w)
Study: 17434171
Drug: Aspirin 500
Normalized name: aspirin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 500 mg pre-treatment
Study: 17434171
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no addition of 500 mg aspirin)
Study: 10233210
Drug: Nabumetone (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (1-2 g daily for up to 4 weeks)
Study: 1781870
Drug: Zidovudine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (1000 mg/day) or placebo
Study: 7552477
Drug: Zidovudine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (500 mg/day)
Study: 1781870
Drug: CD4+ counts
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CD4+ counts less than or equal to 0.2 x 10(9)/l before 30 November 1988
Study: 7082523
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg kg‐1
Study: 7082523
Drug: Thiopentone 3
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 3 mg kg‐1
Study: 21543293
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg once daily for one month
Study: 21543293
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg once daily for one month
Study: 18481715
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at specific acupoints (contralateral scalp motor region, Jiquan (HT 1), Chize (LU 5), Daling (PC 7), Jianyu (LI 15), Tianjing (TE 10), Yangchi (TE 4)) for 3 weeks.
Study: 18481715
Drug: Electro-stimulation treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-stimulation treatment for 3 weeks.
Study: 29660924
Drug: Fluid restrictive
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid restrictive regimen with norepinephrine administration up to 0.04μg/kg/min (FRV)
Study: 29660924
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid administration (LFA)
Study: 24941835
Drug: Yupingfeng Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yupingfeng Powder (YP) combined with routine treatment (inhaled corticosteroids and/or leukotriene regulator)
Study: 24941835
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (inhaled corticosteroids and/or leukotriene regulator)
Study: 15968840
Drug: Functional cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional cognitive-behavioural therapy (FCBT)
Study: 10594471
Drug: SDZ RAD
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ RAD (0.25, 0.75, 2.5, 7.5, 15, 25 mg)
Study: 10594471
Drug: SDZ RAD
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ RAD (2.5-25 mg)
Study: 10594471
Drug: SDZ RAD
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ RAD (0.25-25 mg)
Study: 2011703
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and Senna laxative (X‐prep) combined with a saline enema (n = 88)
Study: 2011703
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol electrolyte lavage solution (Golytely) (n = 90)
Study: 2011703
Drug: Combined regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined regimen of Cascara‐Salax laxative (PicoSalax) and Golytely (n = 93)
Study: 7073570
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin administration before and after surgery
Study: 25759942
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (reflection seminars)
Study: 22759866
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg levobupivacaine (group L)
Study: 22759866
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg tramadol (group T)
Study: 22759866
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg tramadol plus 100 mg levobupivacaine (group LT)
Study: 11505416
Drug: TRAUMEEL S
Normalized name: Traumeel S Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAUMEEL S (mouth rinse, 5 times daily for a minimum of 14 days)
Study: 11505416
Drug: Placebo (mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mouth rinse, 5 times daily for a minimum of 14 days)
Study: 9052357
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and ticlopidine pretreatment
Study: 19781416
Drug: Early abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early abciximab administration (EA) in high-risk patients (n = 413)
Study: 19781416
Drug: Late abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late abciximab administration (LA) in high-risk patients (n = 203)
Study: 19781416
Drug: Early abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early abciximab administration (EA) in low-risk patients (n = 314)
Study: 19781416
Drug: Late abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late abciximab administration (LA) in low-risk patients (n = 156)
Study: 16407020
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate solution
Study: 11237929
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1 g EPA plus DHA daily, containing 720 mg EPA + 280 mg DHA)
Study: 11237929
Drug: ALA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA (2 g daily)
Study: 11237929
Drug: GLA (770
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLA (770 mg daily)
Study: 11237929
Drug: AA (680
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA (680 mg daily)
Study: 11237929
Drug: DHA (720
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (720 mg daily)
Study: 8986685
Drug: Transdermal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal administration of 100 micrograms/d E2
Study: 8362228
Drug: Erythromycin treatment
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin treatment for 7 days
Study: 3496948
Drug: Dipyridamole (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (120 mg/d) by constant intravenous infusion
Study: 3496948
Drug: Isotonic dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic dextrose solution
Study: 30508890
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (90 kVp/395 mAs, contrast agent dosage of 1.2 mL/kg)
Study: 30508890
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (120 kVp/200 mAs, contrast agent dosage of 1.5 mL/kg)
Study: 21357965
Drug: Standard Ponseti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Ponseti method (plaster change weekly)
Study: 18070980
Drug: Levofloxacin, 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin, 1,000 mg daily
Study: 18070980
Drug: Gatifloxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin, 400 mg daily
Study: 18070980
Drug: Moxifloxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin, 400 mg daily
Study: 14679153
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy (n = 360)
Study: 14679153
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (CMF -> goserelin)
Study: 14679153
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (for ER-positive patients)
Study: 11127233
Drug: Insecticide-treated nets
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insecticide-treated nets (ITNs) with permethrin, 0.5 g/m2
Study: 11127233
Drug: Insecticide-treated chaddars
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insecticide-treated chaddars with permethrin, 1 g/m2
Study: 11127233
Drug: Residual spraying
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual spraying of houses with lambdacyhalothrin, 30 mg/m2
Study: 949903
Drug: 0.05% clobetasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasone butyrate cream or ointment
Study: 949903
Drug: 0.0125% flurandrenolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0125% flurandrenolone cream or ointment
Study: 27790789
Drug: Simeprevir 150
Normalized name: simeprevir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir 150 mg and sofosbuvir 400 mg daily for 8 weeks (Group A1, n=20)
Study: 27790789
Drug: Simeprevir 150
Normalized name: simeprevir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir 150 mg and sofosbuvir 400 mg daily for 12 weeks (Group A2, n=20)
Study: 27790789
Drug: Simeprevir 150
Normalized name: simeprevir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir 150 mg and sofosbuvir 400 mg daily for 12 weeks (Group B, n=23)
Study: 25985992
Drug: Mass Testing
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass Testing and Treatment Intervention (MTAT) using rapid diagnostic tests (RDTs) and artemether-lumefantrine (AL)
Study: 25985992
Drug: No Mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Mass Testing and Treatment Intervention (Standard of Care)
Study: 22594858
Drug: Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimoniate (20 mg Sb5/kg weight/day for 20 days)
Study: 17223022
Drug: Bioadhesive formulations
Normalized name: urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioadhesive formulations (LM-5, LM-12, chitosan G210) delivered using a nasal drop device
Study: 17223022
Drug: Pectin formulation
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin formulation administered with a nasal spray system
Study: 17223022
Drug: Bioadhesive formulations
Normalized name: urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioadhesive formulations
Study: 12401244
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (2 g bolus over 15 min, followed by 17 g infusion over 24 h)
Study: 9649951
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + Glipizide (I + G)
Study: 9649951
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + Placebo (I + P)
Study: 1962618
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg hs
Study: 7236871
Drug: Propranolol 5
Normalized name: propranolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 5 mg
Study: 7236871
Drug: Propranolol 20-640
Normalized name: propranolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 20-640 mg d-1
Study: 7236871
Drug: Propranolol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (various doses)
Study: 29121979
Drug: Ticagrelor plus
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor plus Aspirin (TIC + ASP) for 4 weeks
Study: 29121979
Drug: Ticagrelor plus
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor plus Aspirin (TIC + ASP)
Study: 21251179
Drug: LY2189265 (LY)
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY2189265 (LY) 0.1 to 12 mg, single escalating subcutaneous injections
Study: 21251179
Drug: LY2189265 (LY)
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY2189265 (LY) doses ≥1.0 mg
Study: 21251179
Drug: LY2189265 (LY)
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY2189265 (LY) doses ≥3.0 mg
Study: 17593957
Drug: Gatifloxacin 10
Normalized name: GATIFLOXACIN 10MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 10 mg/kg, given once daily for 7 days
Study: 17593957
Drug: Cefixime 20
Normalized name: cefixime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 20 mg/kg/day given in two divided doses for 7 days
Study: 15034229
Drug: Climodien 2/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climodien 2/3 (estradiol valerate 2 mg + dienogest 3 mg)
Study: 11511790
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 20% human albumin followed by 160 mg of furosemide
Study: 11511790
Drug: Sham solution
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham solution followed by 160 mg of furosemide
Study: 7516361
Drug: Total paracentesis
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total paracentesis with dextran‐40 infusion (8 g per liter of ascitic fluid removed)
Study: 7516361
Drug: Total paracentesis
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total paracentesis with dextran‐40 infusion
Study: 2735337
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g four times per day)
Study: 2660562
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg twice per day)
Study: 21843831
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual daily activities)
Study: 24032226
Drug: Combined systemic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined systemic and regional chemotherapy
Study: 17002935
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation; specific dosage and duration not available
Study: 14586909
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy with resistance